Rutherford Health Plc
Bupa and Rutherford Cancer Centres partner
to opennew health clinics
8 November 2021: Rutherford Health plc (AQSE: RUTH, the "Group"), a leading
The move will give customers access to services such as private GP appointments, health assessments and physiotherapy.
Customers using Bupa's clinic will benefit from simple onward referrals. If symptoms of cancer are picked up in the Bupa Health Clinic, patients will be able to see Rutherford's cancer specialists within the cancer centres - which offer MRI and CT scans, mammograms and ultrasonograms - on the same day.
The first clinic opened at Rutherford's Cancer Centre North West in
Incorporating Bupa Health Clinics within its centres further expands the diversity of Rutherford's revenues beyond cancer care.
Mike Moran, CEO of Rutherford Health Plc, said:
"Expanding our relationship with Bupa to provide Bupa Health Clinics at our Rutherford Cancer Centres is an exciting step towards bringing better healthcare to more people. The one-stop clinic offering will enable access to our state-of-the-art diagnostics and treatments for those who need them, while also diversifying our business streams.
"That Bupa chose us to partner with to create new Bupa Health Clinics is a real endorsement of our offering, experienced team and the state-of-the-art, patient centred facilities we have built."
Dr Arun Thiyagarajan, Director at Bupa Health Clinics said:
"When people have cancer concerns, we know it's so important to move quickly, both to get the best prognosis or give them much needed peace of mind. Our partnership with Rutherford Cancer Centres will help give people a quick and easy pathway from diagnosis to treatment, so we're delighted to be launching health clinics within their sites."
The Bupa Health Clinics will have their own entrances and Bupa branding, though will be run in partnership with Rutherford, whose expert team will provide staffing and management. Marketing and patient engagement will be driven by Bupa and the management of the clinics will be supported by Bupa infrastructure including operations, IT support, clinical governance etc.
The information contained within this announcement is deemed to constitute inside information as stipulated under the retained EU law version of the Market Abuse Regulation (EU) No. 596/2014 (the "
-Ends-
For more information, please contact:
Rutherford Health plc |
+44 (0) 16 3381 0661 |
Michael Moran, Chief Executive Officer |
Investors@therutherford.com |
|
|
Grant Thornton (Corporate Adviser) |
+44 (0) 20 7383 5100 |
Colin Aaronson / George Grainger |
|
|
|
Instinctif Partners |
+44 207 457 2020 |
Melanie Toyne-Sewell / Jeremy Durrant / Rozi Morris |
Rutherford@Instinctif.com |
|
|
Media House International |
07788 414 856 / 0207 710 0020 |
Ramsay Smith |
ramsay@mediahouse.co.uk |
|
|
Bupa Laura Tompkins |
07595461287 bupapressoffice@bupa.com |
About Rutherford Health plc
Rutherford Health plc is a leading UK provider of innovative cancer care. Operating a network of four state-of-the-art centres in Wales, Reading, Northumberland and Liverpool, Rutherford Health offers a comprehensive range of the latest technology in cancer treatments, and is the only independent provider of proton beam therapy ("PBT") in the UK. The Company also provides conventional radiotherapy, chemotherapy, immunotherapy, imaging and wellbeing services.
The Group is listed on the Apex segment of the AQSE Growth Market under the symbol: RUTH. For more information, visit the Group's website: www.rutherfordhealth.com.
About Bupa
Bupa's purpose is helping people live longer, healthier, happier lives and making a better world.We are an international healthcare company serving over 31 million customers worldwide. With no shareholders, we reinvest profits into providing more and better healthcare for the benefit of current and future customers.We directly employ around 85,000 people, principally in the UK, Australia, Spain, Chile, Poland, New Zealand, Hong Kong SAR, Turkey, Brazil, Mexico, the US, Middle East and Ireland. We also have associate businesses in Saudi Arabia and India.
For more information, visit www.bupa.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.